Cloud collaborations boost global cancer diagnostics

Cloud collaborations boost global cancer diagnostics

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, and Leica Biosystems, a cancer diagnostics company and global leader in workflow solutions, have agreed an expanded partnership to enhance the use of digital pathology workflows at hospitals and laboratories around the world.

Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence and productivity.

Building on an existing partnership, Leica Biosystems has selected Paige as the preferred provider of Software- as-a-Service (SaaS) digital pathology image management and viewing software along with diverse embedded AI solutions for their line of Aperio GT 450 digital pathology slide scanners.

Leica Biosystems Aperio instrumentation is used in hospitals and laboratories around the world. Under the partnership, a co-branded version of Paige’s Platform will be introduced as the core interface between pathologists and Leica Biosystems hardware.

Users of Aperio GT 450 scanners will have access to Paige’s full suite of digital pathology software.

“Our expanded partnership with Leica Biosystems reflects our unwavering commitment to deliver powerful AI applications to pathologists everywhere,” said Andy Moye, Ph.D., Chief Executive Officer, Paige.

“With the widespread reach of Leica Biosystems scanners, we look forward to providing a seamless end-to-end solution that makes the transition to digital pathology easier for hospitals and laboratories around the world. The goal of our partnership is to help accelerate the ease of adoption of digital pathology and the efficiency with which pathologists can evaluate patient cases and to provide them with the insights needed to take decisive medical action.”

With a heritage of innovation spanning more than 150 years, Leica Biosystems has offered nine generations of continually improving digital slide scanning technology, realized in compact, user-friendly image capture devices that integrate with pathology workflows and laboratory information systems.

Paige’s offerings include novel AI applications together with a powerful platform to easily view and manage whole slide images, putting the power of digital pathology into the hands of pathologists.

“As two global leaders in digital pathology, we have a shared goal of advancing the practice of pathology to improve patient care through innovative hardware and AI-driven software,” said Gustavo Perez, President, Leica Biosystems.

“We believe that Paige’s differentiated platform and transformative portfolio of AI technologies will provide a streamlined user experience and help pathologists rapidly transition to digital workflows, enabling them to continue the fight against cancer.”

Paige has also announced the availability of Mindpeak’s AI algorithms for IHC biomarker quantification in the Paige Platform. 

Mindpeak, a leader in image analysis AI software, brings state-of-the-art AI algorithms for analyzing IHC slides of lung and breast tissue into the Paige Platform.

The combined technologies are pitched as helping pathologists deliver faster, more accurate and more reproducible quantitative cancer diagnoses – even in the most challenging and complex cases.

This new integration allows a complete and seamless workflow on the Paige Platform through FullFocus, Paige’s FDA-cleared whole-slide image viewer, providing case reviewing capabilities and access to AI, including Mindpeak’s quantitative immunohistochemistry products that enable detection, classification and quantification of immunolabeling results for lung and breast cancers.

“The platform offers open compatibility with Mindpeak’s image analysis algorithms and AI solutions to support a complete and optimized workflow experience for pathologists,” said Felix Faber, CEO, Mindpeak.

“Providing access to real-time results for breast and lung cancer IHC biomarkers enhances efficiency and accuracy of diagnosis and treatment planning to benefit pathologists, oncologists and patients, alike,” he said.

“The Paige and Mindpeak integration highlights the Platform’s native AI deployment capabilities and provides real-time quantitative results for routine IHC biomarkers in lung and breast cancer,” said Dr David Klimstra, Co-Founder and Chief Medical Officer, Paige.

“The seamless integration into FullFocus allows pathologists to review all images from patients’ cases and immediately view results from Mindpeak’s AI-algorithms through a single interface at the slide-level or on regions of interest selected by the pathologist, improving day-to-day workflows without the need for multiple viewers and helping pathologists reproducibly quantify the expression of key predictive markers,” he said.

Click below to share this article

Browse our latest issue

Intelligent CIO North America

View Magazine Archive